Oncotelic Therapeutics (OTCQB: OTLC), a developer of oncology and immunotherapy products, announced that its wholly owned subsidiary Pet2DAO, Inc. is inviting scientists, AI developers, and biotech founders to participate in BIO REBOOT, an initiative powered by its PDAOAI artificial intelligence-driven drug discovery platform. Participants can bring research questions, technical expertise, and drug discovery ideas to the PDAOAI community, with selected projects potentially receiving startup funding and Oncotelic support that covers validation, formulation, regulatory planning, and clinical development. This move signals a strategic shift toward democratizing drug discovery and could accelerate the identification of novel therapeutics by leveraging collective expertise and AI.
In addition, Oncotelic revealed that two PDAOAI keynote presentations will be delivered at the 10th International Conference on Drug Discovery & Lead Optimization, scheduled for October 7-9, 2026, in Burlingame, California. Chief Business Officer Saran Saund will present a hepatocellular carcinoma case study demonstrating how Partitioned Literature Aggregation generated a candidate four-gene signature, while Product Manager Scott Myers will discuss AI search aggregation for biomedical knowledge discovery in drug development. These presentations highlight the platform's potential to transform how researchers identify and validate drug targets.
The BIO REBOOT initiative and the upcoming presentations underscore Oncotelic's commitment to advancing its PDAOAI platform as a tool for external collaboration. By inviting outside participants, the company may tap into a broader pool of ideas and talent, potentially leading to new intellectual property and partnerships. For investors, this could mean additional value creation beyond Oncotelic's internal pipeline, which focuses on cancers with substantial unmet needs and rare pediatric indications.
To view the full press release, visit https://ibn.fm/dxB7y. The latest news and updates relating to OTLC are available in the company's newsroom at https://ibn.fm/OTLC.
The announcement was distributed through BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which provides access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions.
For more information, visit https://www.BioMedWire.com. Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer.
